Search

Recursion Pharmaceuticals Inc

Открыт

СекторЗдравоохранение

3.63 5.83

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.61

Макс.

3.66

Ключевые показатели

By Trading Economics

Доход

-14M

-131M

Продажи

1.2M

7.7M

Прибыль на акцию

-0.25

Рентабельность продаж

-1,708.018

Сотрудники

600

EBITDA

-10M

-113M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+77.13% upside

Дивиденды

By Acuity

Следующий отчет о доходах

4 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

135M

1.8B

Предыдущая цена открытия

-2.2

Предыдущая цена закрытия

3.63

Новостные настроения

By Acuity

34%

66%

71 / 339 Рейтинг в Healthcare

Recursion Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 сент. 2026 г., 20:08 UTC

Recursion Pharmaceuticals shares are higher today, continuing an upward trend since Thursday's close, amid broader market dynamics following a strong jobs report.

3 сент. 2026 г., 23:21 UTC

Correlated Moves

Recursion Pharmaceuticals Inc. shares declined in after-market trading, following a peak shortly after the market closed and amid broader market weakness.

2 сент. 2026 г., 23:06 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market trading. The decline comes amid a weaker ADP private payrolls report impacting overall market sentiment.

1 сент. 2026 г., 20:09 UTC

Recursion Pharmaceuticals Inc. shares are lower, following broader market declines amid rising oil prices and increasing U.S. Treasury yields. No specific company news was identified.

31 авг. 2026 г., 23:06 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours. Market sentiment reflects recent comments from Federal Reserve Chair Kevin Warsh on inflation and interest rates.

28 авг. 2026 г., 23:51 UTC

Recursion Pharmaceuticals Inc shares are higher in after-market hours, following three consecutive lower finishes. No specific news was identified to explain the movement.

27 авг. 2026 г., 23:02 UTC

Recursion Pharmaceuticals Inc shares are trading higher in after-market hours. No specific news was identified to explain the price movement.

26 авг. 2026 г., 20:08 UTC

Correlated Moves

Recursion Pharmaceuticals is declining amid a broader downturn in the Biotechnology sub-sector, with the ARK Genomic Revolution ETF also experiencing losses.

25 авг. 2026 г., 23:01 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

24 авг. 2026 г., 20:02 UTC

News
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower amid broader market declines, with analysts rating the stock as a "Hold" and price targets between $5.30 and $10.00.

21 авг. 2026 г., 20:06 UTC

Recursion Pharmaceuticals Inc shares are higher during Friday's session, reflecting strong momentum since Thursday's close amid favorable conditions in the biotechnology sector.

20 авг. 2026 г., 20:06 UTC

Social Media
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today, reflecting broader market trends. The stock's decline aligns with weakness in correlated assets.

19 авг. 2026 г., 23:01 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours after a volatile session, declining from the upper end of its one-month range.

18 авг. 2026 г., 20:04 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today amid broader market pressures on small-cap stocks and rising U.S. Treasury yields affecting sentiment.

17 авг. 2026 г., 19:36 UTC

Correlated Moves
News

Recursion Pharmaceuticals shares decline as Morgan Stanley cuts the price target to $5.30 from $5.50, reflecting ongoing valuation concerns.

12 авг. 2026 г., 19:56 UTC

Recursion Pharmaceuticals Inc is trading lower, reflecting a decline from Tuesday's close. The stock remains above its 20-day moving average despite today's pullback.

11 авг. 2026 г., 19:36 UTC

News

Recursion Pharmaceuticals Inc. is higher today amid positive market sentiment and over $500 million in milestone payments from partnerships with Genentech/Roche and Sanofi.

10 авг. 2026 г., 20:06 UTC

Social Media

Recursion Pharmaceuticals Inc is higher Monday amid ongoing interest, despite social media concerns about its clinical pipeline and integration challenges with Exscientia.

7 авг. 2026 г., 23:26 UTC

Recursion Pharmaceuticals Inc. shares have been roughly flat in after-market trading, with minimal fluctuations since Friday's close. The stock remains above its 20-day moving average.

6 авг. 2026 г., 23:26 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid a strengthening U.S. Dollar.

5 авг. 2026 г., 23:41 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, amid declining sentiment in US markets despite positive momentum in Asian indices.

4 авг. 2026 г., 23:31 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours following a volatile session with no specific news to explain the movement.

3 авг. 2026 г., 20:03 UTC

Correlated Moves
News

Recursion Pharmaceuticals Inc shares are higher amid strong market sentiment, supported by a rise in the Russell 2000 Index and notable intraday volatility.

31 июл. 2026 г., 23:32 UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

30 июл. 2026 г., 23:26 UTC

Recursion Pharmaceuticals Inc. shares were roughly flat in after-market hours, trading within a narrow range since Thursday's close, significantly below its 20-day moving average.

29 июл. 2026 г., 22:51 UTC

Recursion Pharmaceuticals Inc is higher in after-market trading, reflecting broader market gains amid the Federal Reserve's decision to maintain interest rates.

28 июл. 2026 г., 23:11 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares declined in after-market hours, influenced by a broader market downturn and declines in tech stocks amid AI investment concerns.

27 июл. 2026 г., 23:46 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower in after-market trading, reflecting broader market trends despite gains in the DAX 30 Index amid mixed results across indices.

24 июл. 2026 г., 23:11 UTC

Recursion Pharmaceuticals Inc shares rose during after-market hours, gaining momentum despite being near the lower end of their one-month trading range.

23 июл. 2026 г., 19:16 UTC

Recursion Pharmaceuticals Inc. shares are trading roughly flat, remaining below their 20-day moving average amid limited upward momentum in broader market dynamics.

Сравнение c конкурентами

Изменение цены

Recursion Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

77.13% рост

Прогноз на 12 месяцев

Средняя 6.43 USD  77.13%

Максимум 8 USD

Минимум 5.3 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Recursion Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

4 ratings

1

Покупка

3

Удержание

0

Продажа

Настроения

By Acuity

71 / 339Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat